NCT07339085 Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
| NCT ID | NCT07339085 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jonsson Comprehensive Cancer Center |
| Condition | Malignant Brain Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2025-08-28 |
| Primary Completion | 2030-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2025-08-28 with a primary completion date of 2030-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether advanced magnetic resonance imaging (MRI) techniques, including diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, can be used to identify the difference between brain tumors that come back after a period of improvement (recurrent) and treatment-related tissue damage (radiation necrosis \[RN\]). Radiation therapy is often used in the treatment of brain tumors. Radiation treatment response can be difficult to assess and is usually done using conventional MRI, which uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. Current imaging techniques have a limited ability to identify the difference between recurrent brain tumor and RN due to their similar appearance on conventional MRI and overlapping clinical presentation. This makes it hard for doctors to plan the best way to treat these tumors. DR-CSI is a new MRI technique with the potential to detect microscopic tissue components with different characteristics. Sodium imaging is an MRI technique that estimates the total sodium concentration in the obtained images. It may be able to identify the small structures within the tissue of brain tumors. Advanced MRI techniques like DR-CSI and sodium imaging may be effective in identifying the difference between recurrent brain tumors and RN.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years old * Diagnosed with metastatic brain tumor * AIM 1: Scheduled for surgical resection or tissue biopsy +/- laser interstitial thermal therapy (LITT) * AIM 2: Scheduled for SRS treatment Exclusion Criteria: * Patients with contraindications to MRI, severe renal impairment * Patients with evidence of disseminated leptomeningeal disease
Contact & Investigator
Jingwen Yao
PRINCIPAL INVESTIGATOR
UCLA / Jonsson Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT07339085 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Brain Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07339085 currently recruiting?
Yes, NCT07339085 is actively recruiting participants. Visit ClinicalTrials.gov or contact Jonsson Comprehensive Cancer Center to inquire about joining.
Where is the NCT07339085 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07339085 clinical trial?
NCT07339085 is sponsored by Jonsson Comprehensive Cancer Center. The principal investigator is Jingwen Yao at UCLA / Jonsson Comprehensive Cancer Center. The trial plans to enroll 42 participants.